These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2646492)

  • 1. Assessing patients' utilities. Can the ends justify the means?
    Mulley AG
    Med Care; 1989 Mar; 27(3 Suppl):S269-81. PubMed ID: 2646492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferences for health outcomes and cost-utility analysis.
    Torrance GW
    Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility assessment among patients with dry eye disease.
    Schiffman RM; Walt JG; Jacobsen G; Doyle JJ; Lebovics G; Sumner W
    Ophthalmology; 2003 Jul; 110(7):1412-9. PubMed ID: 12867401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index.
    Dan AA; Kallman JB; Srivastava R; Younoszai Z; Kim A; Younossi ZM
    Liver Transpl; 2008 Mar; 14(3):321-6. PubMed ID: 18306356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the treatment tradeoff method in rectal cancer patients: is surgery preference related to outcome utilities?
    Bossema ER; Marijnen CA; Baas-Thijssen MC; van de Velde CJ; Stiggelbout AM
    Med Decis Making; 2008; 28(6):888-98. PubMed ID: 18519887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinician's guide to utility measurement.
    Redelmeier DA; Detsky AS
    Prim Care; 1995 Jun; 22(2):271-80. PubMed ID: 7617786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Family pediatrics: report of the Task Force on the Family.
    Schor EL;
    Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health related utility measurement: an introduction.
    Bakker C; van der Linden S
    J Rheumatol; 1995 Jun; 22(6):1197-9. PubMed ID: 7674256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health state utilities in knee replacement surgery: the development and evaluation of McKnee.
    Bennett KJ; Torrance GW; Moran LA; Smith F; Goldsmith CH
    J Rheumatol; 1997 Sep; 24(9):1796-805. PubMed ID: 9292806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A health outcomes framework for assessing health status and quality of life: enhanced data for decision making.
    Erickson P
    J Natl Cancer Inst Monogr; 2004; (33):168-77. PubMed ID: 15504927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
    Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decision analysis in forensic science.
    Taroni F; Bozza S; Aitken C
    J Forensic Sci; 2005 Jul; 50(4):894-905. PubMed ID: 16078494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Erectile Function Visual Analog Scale (EF-VAS): a disease-specific utility instrument for the assessment of erectile function.
    Casey R; Tarride JE; Keresteci MA; Torrance GW
    Can J Urol; 2006 Apr; 13(2):3016-25; discussion 3026. PubMed ID: 16672112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel computer based expert decision making model for prostate cancer disease management.
    Richman MB; Forman EH; Bayazit Y; Einstein DB; Resnick MI; Stovsky MD
    J Urol; 2005 Dec; 174(6):2310-8. PubMed ID: 16280831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians.
    Bennett CL; Chapman G; Elstein AS; Knight SJ; Nadler RB; Sharifi R; Kuzel T
    Eur Urol; 1997; 32 Suppl 3():86-8. PubMed ID: 9267792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Utility assessment in clinical decision making].
    Verhoef CG; Verbeek AL; Stalpers LJ; van Daal WA
    Ned Tijdschr Geneeskd; 1990 Nov; 134(45):2195-200. PubMed ID: 2247189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.